Table 1 Clinical samples obtained from the CDC to assess the specificity of the xVFA and the corresponding ground truth information
Sample group | Standard two-tier tests (STTT) | Modified two-tier tests (MTTT) | Diagnosis | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
IgM/IgG EIA | IgM WB | IgG WB | Zeus VlsE/pepC10 EIA | Zeus WCS EIA | Zeus IgM EIA | Zeus IgG EIA | STTT | MTTT IgM | MTTT IgG | xVFA | |
Early Lyme-acute | 0/4 | 1/4 | 0/4 | 2/4 | 1/4 | 1/4 | 0/4 | 0/4 | 1/4 | 0/4 | 0/4 |
Early Lyme- convalescent | 4/4 | 4/4 | 1/4 | 4/4 | 4/4 | 4/4 | 1/4 | 4/4 | 4/4 | 1/4 | 4/4 |
Late Lyme disease | 4/4 | 2/4 | 4/4 | 4/4 | 4/4 | 4/4 | 4/4 | 4/4 | 4/4 | 4/4 | 4/4 |
Look-alike diseases | 2/12 | 0/12 | 0/12 | 1/12 | 1/12 | 1/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 |
Healthy control | 2/8 | 0/8 | 0/8 | 0/8 | 3/8 | 3/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 |
